EA201201050A1 - Пиразолы в качестве антагонистов crth2 - Google Patents

Пиразолы в качестве антагонистов crth2

Info

Publication number
EA201201050A1
EA201201050A1 EA201201050A EA201201050A EA201201050A1 EA 201201050 A1 EA201201050 A1 EA 201201050A1 EA 201201050 A EA201201050 A EA 201201050A EA 201201050 A EA201201050 A EA 201201050A EA 201201050 A1 EA201201050 A1 EA 201201050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazoles
compounds
crth2
antagonists
antagonists crth2
Prior art date
Application number
EA201201050A
Other languages
English (en)
Other versions
EA022280B1 (ru
Inventor
Торстен Ост
Ральф Андерскевитц
Дитер Вольфганг Хампрехт
Кристоф Хёнке
Домник Мартирес
Вольфганг Рист
Петер Зайтер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112128&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201050A1 publication Critical patent/EA201201050A1/ru
Publication of EA022280B1 publication Critical patent/EA022280B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

Настоящее изобретение относится к пиразолам формулы (I) и их фармацевтически приемлемым солям, обладающим активностью в отношении CRTH2, где значения W, L, L, X, L, Y, Rи Rявляются такими, как определено в описании и формуле изобретения, к применению указанных соединений в качестве лекарственных средств и к фармацевтическим составам, содержащим указанные соединения или содержащим комбинацию указанных соединений с одним или более активных веществ.
EA201201050A 2010-01-27 2011-01-24 Пиразолы в качестве антагонистов crth2 EA022280B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151785 2010-01-27
PCT/EP2011/050910 WO2011092140A1 (en) 2010-01-27 2011-01-24 Pyrazole compounds as crth2 antagonists

Publications (2)

Publication Number Publication Date
EA201201050A1 true EA201201050A1 (ru) 2013-02-28
EA022280B1 EA022280B1 (ru) 2015-12-30

Family

ID=42112128

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201050A EA022280B1 (ru) 2010-01-27 2011-01-24 Пиразолы в качестве антагонистов crth2

Country Status (37)

Country Link
US (1) US8791272B2 (ru)
EP (1) EP2528901B9 (ru)
JP (1) JP5658284B2 (ru)
KR (2) KR101812000B1 (ru)
CN (3) CN108383789A (ru)
AP (1) AP3360A (ru)
AR (1) AR080032A1 (ru)
AU (1) AU2011209286B2 (ru)
BR (1) BR112012018695A2 (ru)
CA (1) CA2788224C (ru)
CL (1) CL2012001836A1 (ru)
CO (1) CO6511272A2 (ru)
CY (1) CY1116641T1 (ru)
DK (1) DK2528901T3 (ru)
EA (1) EA022280B1 (ru)
ES (1) ES2545865T3 (ru)
GE (1) GEP20146177B (ru)
HK (1) HK1176062A1 (ru)
HR (1) HRP20150898T1 (ru)
HU (1) HUE025318T2 (ru)
IL (1) IL220208A (ru)
MA (1) MA33937B1 (ru)
MX (1) MX353000B (ru)
MY (1) MY160036A (ru)
NZ (1) NZ600637A (ru)
PE (1) PE20121519A1 (ru)
PL (1) PL2528901T3 (ru)
PT (1) PT2528901E (ru)
RS (1) RS54176B1 (ru)
SG (1) SG182684A1 (ru)
SI (1) SI2528901T1 (ru)
TN (1) TN2012000371A1 (ru)
TW (1) TWI499416B (ru)
UA (1) UA110025C2 (ru)
UY (1) UY33201A (ru)
WO (1) WO2011092140A1 (ru)
ZA (1) ZA201204335B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33937B1 (fr) 2010-01-27 2013-01-02 Boehringer Ingelheim Int Composes pyrazole comme antagonistes du recepteur crth2
CA2818993A1 (en) * 2010-11-24 2012-05-31 Allergan, Inc. Modulators of s1p receptors
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
CN103113303A (zh) * 2011-11-16 2013-05-22 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的氮杂环化合物
JP5893155B2 (ja) 2011-11-17 2016-03-23 山▲東▼亨利医▲薬▼科技有限▲責▼任公司 Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物
WO2013101598A1 (en) * 2011-12-27 2013-07-04 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
US10130609B2 (en) 2013-03-13 2018-11-20 University Health Network Pyrazole derivatives and their uses thereof
CN103265537B (zh) * 2013-05-14 2015-05-27 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3140002A1 (en) 2019-06-06 2020-12-10 Basf Se Fungicidal n-(pyrid-3-yl)carboxamides
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828914B1 (ru) * 1969-04-11 1973-09-05
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
BE759032A (fr) * 1969-11-17 1971-04-30 Takeda Chemical Industries Ltd Acide 3,5-diphenyl-4-pyrazole acetique ou ses derives 1-substitues ou leurs esters
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
EP1228067B1 (en) * 1999-11-10 2004-07-14 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体
JP2003073377A (ja) * 2001-06-20 2003-03-12 Takeda Chem Ind Ltd ５員複素環誘導体
YU30504A (sh) * 2001-09-25 2006-08-17 Pharmacia Corporation Postupak za dobijanje supstituisanih pirazola
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
DE602004011966T2 (de) 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
WO2007141267A1 (en) 2006-06-06 2007-12-13 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
DE602008005582D1 (de) 2007-05-10 2011-04-28 Glaxo Group Ltd Pyrazolderivate als p2x7-modulatoren
NZ584351A (en) 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
AU2008305632B2 (en) * 2007-09-25 2014-01-30 Actimis Pharmaceuticals, Inc. Alkylthio pyrimidines as CRTH2 antagonists
GB0719521D0 (en) * 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
EP2307382B1 (en) * 2008-07-15 2011-12-21 F. Hoffmann-La Roche AG Aminotetrahydroindazoloacetic acids
MA33937B1 (fr) 2010-01-27 2013-01-02 Boehringer Ingelheim Int Composes pyrazole comme antagonistes du recepteur crth2

Also Published As

Publication number Publication date
AP2012006313A0 (en) 2012-06-30
IL220208A (en) 2016-11-30
EA022280B1 (ru) 2015-12-30
DK2528901T3 (en) 2015-08-17
SI2528901T1 (sl) 2015-10-30
KR101906791B1 (ko) 2018-10-11
KR20170142217A (ko) 2017-12-27
PL2528901T3 (pl) 2015-11-30
PT2528901E (pt) 2015-10-13
EP2528901B9 (en) 2017-01-25
ZA201204335B (en) 2019-08-28
AP3360A (en) 2015-07-31
MX353000B (es) 2017-12-15
UA110025C2 (xx) 2015-11-10
TWI499416B (zh) 2015-09-11
ES2545865T3 (es) 2015-09-16
GEP20146177B (en) 2014-10-10
CO6511272A2 (es) 2012-08-31
UY33201A (es) 2011-08-31
CA2788224C (en) 2015-07-21
KR20120117841A (ko) 2012-10-24
EP2528901A1 (en) 2012-12-05
AU2011209286B2 (en) 2016-02-11
CN104829535A (zh) 2015-08-12
WO2011092140A1 (en) 2011-08-04
PE20121519A1 (es) 2012-12-02
NZ600637A (en) 2014-07-25
HRP20150898T1 (hr) 2015-10-09
CA2788224A1 (en) 2011-08-04
SG182684A1 (en) 2012-08-30
US20120028938A1 (en) 2012-02-02
CL2012001836A1 (es) 2012-11-23
AR080032A1 (es) 2012-03-07
CN102884051A (zh) 2013-01-16
TN2012000371A1 (en) 2014-01-30
IL220208A0 (en) 2012-07-31
KR101812000B1 (ko) 2017-12-26
CY1116641T1 (el) 2017-03-15
JP5658284B2 (ja) 2015-01-21
HUE025318T2 (en) 2016-02-29
MX2012008361A (es) 2012-08-08
EP2528901B1 (en) 2015-05-27
TW201138769A (en) 2011-11-16
MY160036A (en) 2017-02-15
BR112012018695A2 (pt) 2016-04-12
US8791272B2 (en) 2014-07-29
MA33937B1 (fr) 2013-01-02
AU2011209286A1 (en) 2012-07-05
JP2013518074A (ja) 2013-05-20
RS54176B1 (en) 2015-12-31
HK1176062A1 (zh) 2013-07-19
CN108383789A (zh) 2018-08-10
CN102884051B (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201401351A1 (ru) Производные бензимидазол-пролина
UA108640C2 (ru) Производные n-(имидазопиримидин 7-ил) гетероариламидов и их применение в качестве ингибиторов pde10a
TR201904614T4 (tr) Novel pyrazole derivative.
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201270216A1 (ru) Фармацевтический состав
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
EA201390799A1 (ru) Триазолопиридины
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
TR201902057T4 (tr) Tetrasiklin bileşikleri.
PH12018501531A1 (en) Pyrazole compounds as crth2 antagonists
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
MX2014014308A (es) Pirrolidino heterociclos.
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
EA201290229A1 (ru) Производные спиролактама и их применение
EA201490573A1 (ru) Соединение бензотиазолона
EA201291401A1 (ru) НОВЫЕ ПРОТИВОГРИБКОВЫЕ ПРОИЗВОДНЫЕ 5,6-ДИГИДРО-4-[(ДИФТОРЭТИЛ)ФЕНИЛ]-4H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА И 4-(ДИФТОРЭТИЛ)ФЕНИЛ-6H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title